About Us

Everest Medicines is a late clinical-stage biopharmaceutical company focused on licensing, developing and commercializing globally innovative therapies with the mission of addressing critical unmet medical needs in Greater China and other emerging Asia Pacific markets.

Our Approach

China has emerged as the second-largest pharmaceutical market in the world, where a growing patient population, significant unmet medical needs, new regulatory reforms and expanding reimbursement are driving demand for high quality, innovative medicines.

Pipeline

Each of our portfolio of eight novel, clinical-stage drug candidates has the potential to become a best-in-class or first-in-class treatment for patients.

Our Purpose

We are united by our purpose to improve lives with our innovative medicines.

Our Commitment

We are committed to highest quality, integrity and excellence in how we conduct our business and achieve our goals.

Organization & Management Team

Since our inception in 2017, we have assembled an experienced and visionary management team, and in-licensed eight late-stage drug candidates in four major therapeutic areas: oncology, immunology, cardio-renal disease and infectious disease.

Read More

Kerry Blanchard, M.D., Ph.D.

Chief Executive Officer

Ian Woo

President and Chief Financial Officer

Neo Xiaofan Zhang

Chief Operating Officer

Jason Brown, Ph.D.

Chief Business Officer

Yang Shi

Chief Medical Officer, Oncology

Sunny Xu Zhu

Chief Medical Officer, Infectious Disease

Zhengying Zhu, M.D., Ph.D.

Chief Medical Officer, Internal Medicine

Steven Xinhui Hu, Ph.D.

Chief Technology Officer

Sophia Yunfan Zhu

Senior Vice President, Portfolio Development and Strategic Planning

Frank Grams

Senior Vice President, Alliance Management and Head of Business Development in Europe

NEWS AND EVENTS

 Copyright Everest Medicines 2020   苏ICP备20038571号 |  Terms of Use |  Privacy Policy |  Disclaimers